

**NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)****Bladder Cancer****Third Guideline Development Group (GDG) meeting**25<sup>th</sup> February 2013

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

**GROUP MEMBERSHIP & ACTION LIST**

<b>GDG Members</b>	
Julia Verne (JV)	William Turner (WT)
Rob Jones (RJ)	Robert Huddart (RH)
Ben Taylor (BT)	Hugh Mostafid (HM)
Helen Chilcott (HC)	Ashish Chandra (ACha)
Ananya Choudhury (ACh)	Jonathan Osborn (JO)
Pauline Bagnall (PB)	
<b>NCC-C staff</b>	
John Graham (JG)	Nathan Bromham (NB)
Elise Hasler (EH)	Matthew Prettyjohns (MP)
Jennifer Hilgart (JH)	Lianne Gwillim (LG)
<b>NICE staff &amp; Affiliated staff</b>	
Claire Turner (CT)	Luke Hounsome (LH)
<b>Apologies</b>	
Phil Kelly (PK)	Louise Warren (LW)
James Catto (JC)	

**REPORTS OF DISCUSSIONS AT THE MEETING****1. Introductions**

JV welcomed everyone to the 3<sup>rd</sup> meeting of the Bladder Cancer GDG. Apologies for absence were received from James Catto, Phil Kelly and Louise Warren.

**2. Declaration of Interest**

The following interests were declared by GDG members on application:

- WT declares that he is a member of the project group of Addenbrookes Urology patient information project (AUIP) trying to improve shared and informed decision making. This interest was categorised personal non-pecuniary meaning that WT can participate in discussion on all shared and informed decision making s not being investigating by guideline
- WT declares that he is the lead of medical advisory group on Bladder cancer in the NHS right care programme, the decision aid in being developed by Totally Health. This interest was categorised personal non-pecuniary meaning that WT can participate in discussion on all topics as decision aids are not being investigating by guideline
- HM declared that he had an agreement with Kyowa to provide occasional advice on issues regarding intravesical chemotherapy. Agreement was formally terminated in February 2012. This interest was categorised personal pecuniary

non-specific meaning that HM must withdraw from discussion on all topics regarding intravesical chemotherapy until February 2013. Topics F and G.

- HM declared that he was a co-applicant on the trial management group for an NIHR funded trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment or other standard treatment for bladder cancer. This interest was categorised as non-personal pecuniary specific, meaning that HM must withdraw from discussions on topic regarding Intravesical chemotherapy and BCG.
- HM declared that is a chief investigator, involved in developing the trial protocol on a NIHR funded trial for standard surgical management of patients with low risk bladder cancer versus intravesical chemotherapy. This interest was categorised as non-personal pecuniary specific, meaning that HM must withdraw discussions on topic on intravesical chemotherapy and surgery.
- JO declared that he is director of Russell Osborn management company. This interest was categorised as personal pecuniary non-specific, meaning that JO can participate on discussion on all topics in the guideline as interest does not relate to healthcare industry.
- JO declared that he Director of Vosper International Ltd, ship design company. This interest was categorised as personal pecuniary non-specific, meaning that JO can participate on discussion on all topics in the guideline as interest does not relate to healthcare industry
- BT declared that he received an honorarium in November 2011 from Novartis for lecture on recent advances and current strategies in GIST's. This interest was categorised as personal pecuniary non-specific meaning that BT can participate in discussion on all topics as GIST is not being investigated by the guideline.
- BT declared that he is chief investigator, involved in developing trial protocol for a study of buscopan to improve image quality in pelvic MRI. Funded by Christie Charitable Funds. This interest was categorised as non-pecuniary non-specific meaning that BT can participate in discussion on all topics as image quality of MRI is not being investigated by the guideline.
- BT declared that he chief investigator, involved in developing trial protocol for a study on diffusion weighted imaging in pelvic MRI. Funded by radiology department, The Christie. This interest was categorised as non-pecuniary non-specific meaning that BT can participate in discussion on all topics as diffusion weighted imaging of MRI is not being investigated by the guideline.
- BT declared that he is a member of the Royal College of Radiologists Guideline Group, involved in writing guideline for imaging of lymphoma. This interest was categorised as personal non-pecuniary meaning that BT can participate in discussion on all topics as lymphoma is not being investigated by the guideline.
- BT declared that he is a member of the NCAT reference group for peer review measures on carcinoma of unknown primary. This interest was categorised as personal non-pecuniary meaning that BT can participate in discussion in all topics as carcinoma of unknown primary is not being investigated by the guideline.
- JC declared that he received an honorarium from GlaxoSmithKline regarding the use of Dutasteride for prostate cancer. This interest was categorised as personal pecuniary non-specific meaning that JC can participate on discussion on all topics as prostate cancer is not being investigated by the guideline.
- JC declared that he was on a scientific advisory board of Orion Pharma regarding the development of an agent to treat prostate cancer. This interest was categorised as personal pecuniary non-specific meaning that JC can participate on discussion on all topics as prostate cancer is not being investigated by the guideline.

- JC declared that he received an honorarium from Astellas for advisory board on Enzalutamide for prostate cancer. This interest was categorised as personal pecuniary non-specific meaning that JC can participate on discussion on all topics as prostate cancer is not being investigated by the guideline.
- ACha declared that he gave a presentation given on benign and malignant serous effusion cytology for the American Society of Cytopathology in November 2012. This interest was categorised as personal non-pecuniary meaning that ACha can participate in discussion on all topics as benign and malignant serous effusion cytology is not being investigated by the guideline.
- ACha declared that he is co-Author of pathology dataset for bladder cancer. This interest was categorised as personal non-pecuniary meaning that ACha can participate in discussion on all topics as pathology datasets are not being investigated by the guideline.
- ACha declared that he is a collaborator providing pathology input for the correlation of distribution of tumour in the prostate based histoscanning and comparing results on template biopsy and radical prostatectomy specimens. Funded by Kings College London. This interest was categorised as non-personal pecuniary non-specific, meaning that ACha can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.
- ACha declared that he is a collaborator providing pathology input for the trans-atlantic prostate group studies using tissue microarrays of prostate tissue collected retrospectively from a cohort of UK patients. Funded by Kings College London. This interest was categorised as non-personal pecuniary non-specific, meaning that ACha can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.
- ACha declared that he is a collaborator providing pathology input for evaluating the role of TMPRSS2-ERG antibody is predicting hormone sensitivity of prostate cancer and supervisor of the MSc project. Funded by Kings College London. This interest was categorised as non-personal pecuniary non-specific, meaning that ACha can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.
- ACha declared that he is a collaborator providing pathology input for collaboration with Harvard University to explore the role of lipid metabolism in prostate cancer tissue microarrays from UK patients. Funded by Kings College London. This interest was categorised as non-personal pecuniary non-specific, meaning that ACha can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.
- ACh declared that she received honorarium from Jaansun for giving a lecture on prostate cancer in September 2011. This interest was categorised as personal pecuniary non-specific meaning that ACh can participate in discussions on all topics as prostate cancer is not being investigated by the guideline.
- ACh declared that she is a principle investigator on the mainsail trial to evaluate the safety and effectiveness of lenalidomide in combination with docetaxel and prednisone for patients with castrate-resistant prostate cancer. Not involved in trial protocol and is funded by Celgene Corporation. This interest was categorised as non-personal pecuniary non-specific meaning that ACh can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.
- ACh declared that she is a principle investigator on the AFFIRM trial to evaluate the safety and efficacy of MDV3100 in patients with castrate-resistant prostate cancer, who have previously been treated with docetaxel-based chemotherapy. Not involved in trial protocol and is funded by Medivation Inc. This interest was

categorised as non-personal pecuniary non-specific meaning that ACh can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.

- ACh declared that she is a chief investigator and involved in the trial protocol of the trial of the simultaneous cone beam computed tomography (CBCT) acquisition during Arc radiotherapy in prostate cancer. Funded by Christie Charitable Funds. This interest was categorised as non-personal pecuniary non-specific meaning that ACh can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.
- ACh declared that she a chief investigator and involved in the trial protocol of a phase I feasibility study to compare early response assessment and planning volumes with contract-enhanced computer tomography (CT), MRI including diffusion weighted MRI (DWI) and dynamic-contrast enhanced (DCE) MRI in patients with limb sarcoma undergoing pre-operative radiotherapy. Funded by Christie Charitable Funds. This interest was categorised as non-personal pecuniary non-specific meaning that ACh can participate in discussion on all topics as limb sarcoma is not being investigated by the guideline.
- ACh declared that she is a chief investigator for a study looking at the role of rectal balloons in prostate radiotherapy (BRAD). Funded by Men Matter Charity. This interest was categorised as non-personal pecuniary non-specific meaning that ACh can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.
- RJ declared that he received honoraria from Janssen for a consultancy on prostate cancer in November 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as prostate cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Janssen for speaking on prostate cancer in September 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as prostate cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Pfizer for a consultancy on renal cancer in November 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Pfizer for speaking on renal cancer in June 2011. . This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Pfizer for speaking on renal cancer in October 2011. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Pfizer for speaking on renal cancer in November 2011. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Novartis for a consultancy on renal cancer in August 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Sanofi-Aventis for a consultancy on prostate cancer in November 2011. This interest was categorised as personal

pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.

- RJ declared that he received honoraria from Sanofi-Aventis for a consultancy on prostate cancer in July 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as prostate cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Sanofi-Aventis for speaking on prostate cancer in October 2011. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as prostate cancer is not being investigated by guideline.
- RJ declared that he received honoraria from GlaxoSmithKline for speaking on renal cancer in June 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from GlaxoSmithKline for speaking on renal cancer in November 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Astellas for a consultancy on renal cancer in March 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Astellas for a consultancy on renal cancer in March 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cancer is not being investigated by guideline.
- RJ declared that he received honoraria from AstraZeneca for a consultancy on the development of a specific non marketed product for prostate cancer in January 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as prostate cancer is not being investigated by guideline.
- RJ declared that he received honoraria from AstraZeneca for a consultancy on prostate cancer in January 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as prostate cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Curevac for a consultancy on prostate cancer in November 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as prostate cancer is not being investigated by guideline.
- RJ declared that he received honoraria from Roche for a consultancy on access to cancer medicines in Scotland in March 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as access to cancer medicines in Scotland is not being investigated by guideline.
- RJ declared that he received reimbursement of travel expenses from GlaxoSmithKline for attending ASCO meeting on a marketed product for renal cell cancer in May 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cell cancer is not being investigated by guideline.
- RJ declared that he received reimbursement of travel expenses from GlaxoSmithKline for attending a ESMO meeting on renal cell cancer in October 2012. This interest was categorised as personal pecuniary non-specific meaning

that RJ can participate in discussion in all topics as renal cell cancer is not being investigated by guideline.

- RJ declared that he received honoraria from Dendreon for a consultancy on prostate cancer in November 2012. This interest was categorised as personal pecuniary non-specific meaning that RJ can participate in discussion in all topics as renal cell cancer is not being investigated by guideline.
- RJ declared that he is chief investigator for MAdCap, for prostate cancer, funded by Roche. This interest was categorised as non-personal pecuniary, non-specific, meaning that RJ can participate in discussion on all topics as prostate cancer is not being investigated by the guideline.
- RJ declared that he is chief investigator for ASPEN, for renal cancer, funded by Novartis and Pfizer. This interest was categorised as non-personal pecuniary, non-specific, meaning that RJ can participate in discussion on all topics as renal cancer is not being investigated by the guideline.

The following interest was declared at the meeting:

- RJ declared that he was paid by Bayer for consultancy advice on sorafenib in renal cell carcinoma. This has been categorised as personal pecuniary non-specific meaning that Rob can participate in discussion on all topics as renal cell carcinoma is not being investigated by the guideline.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that necessary action can be taken.

### 3. Discussion

The GDG discussed and agreed the review questions and PICO's for topics, E, F1a & B, F2, G2, H1, H2, H3, H4, H5, K1, K2.

An update was given on health economics and the GDG agreed that topic K1 was the highest priority topic for health economic modelling.

The GDG agreed the draft recommendations, research recommendations and LETR's for topics I and M.

### 4. Close of meeting

JV thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Tuesday 23<sup>rd</sup> April** starting at 10.30am in the **Bollin Room, NICE, City Tower, Piccadilly Plaza Manchester M1 4BT** and closed the meeting.